600|6558|Public
25|$|Estrogen is {{considered}} to {{play a significant role}} in women’s mental health, with links suggested between the <b>hormone</b> <b>level,</b> mood and well-being. Sudden drops or fluctuations in, or long periods of sustained low levels of estrogen may be correlated with significant mood-lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized and/or restored.|$|E
2500|$|The {{evaluation}} of atrial fibrillation involves {{a determination of}} {{the cause of the}} arrhythmia, and classification of the arrhythmia. [...] Diagnostic investigation of AF typically includes a complete history and physical examination, ECG, transthoracic echocardiogram, complete blood count, and serum thyroid stimulating <b>hormone</b> <b>level.</b>|$|E
2500|$|Genetic {{screening}} for Down syndrome (trisomy 21) and trisomy 18, the national {{standard in the}} United States, is rapidly evolving away from the AFP-Quad screen for Down syndrome, done typically in the second trimester at 16–18 weeks. The newer integrated screen (formerly called F.A.S.T.E.R for First And Second Trimester Early Results) can be done at 10 plus weeks to 13 plus weeks with an ultrasound of the fetal neck (thicker nuchal skin correlates with higher risk of Down syndrome being present) and two chemicals (analytes) PAPP-A and βHCG (pregnancy <b>hormone</b> <b>level</b> itself). It gives an accurate risk profile very early. A second blood screen at 15 to 20 weeks refines the risk more accurately. The cost is higher than an [...] "AFP-quad" [...] screen due to the ultrasound and second blood test, but it is quoted to have a 93% pick up rate as opposed to 88% for the standard AFP/QS. This is an evolving standard of care in the United States.|$|E
40|$|The {{objective}} {{of this study is}} to evaluate <b>hormone</b> <b>levels</b> in premenopausal females with breast cancer at the time of diagnosis and to predict their role as a risk factor of breast cancer in females. Circulating <b>hormone</b> <b>levels</b> were measured in 345 previously untreated premenopausal breast cancer patients during luteal phase (19 th- 21 st day). Their results were compared with a group of 345 age-matched healthy controls. Serum prolactin, testosterone, estrogen and progesterone levels were higher in patients as compared to controls. Regression analysis showed that changes in <b>hormone</b> <b>levels</b> have significant impact on breast cancer. Female patients with breast cancer have abnormalities in <b>hormone</b> <b>levels.</b> These abnormalities may be considered in the pathogenesis of the disease and should be taken into account for the treatment of patients of breast cancer. Reduction of <b>hormone</b> <b>levels</b> might prove to be helpful in preventing breast cancer but further studies are required to prove the benefit of analyzing <b>hormone</b> <b>levels</b> at an early stage...|$|R
40|$|Basal plasma growth <b>hormone</b> <b>levels</b> {{as well as}} growth <b>hormone</b> <b>levels</b> during insulin -induced {{hypoglycemia}} {{have been}} studied in 19 cases with osteoporosis, in 34 patients with primary osteoarthrosis and in 19 control subjects. Women with primary osteoarthrosis had basal growth <b>hormone</b> <b>levels</b> significantly higher than control patients and patients with osteoporosis. The respective mean values and SE were: 4. 9 +/- 0. 8 vs. 1. 9 +/- 0. 8 and 1. 3 +/- 0. 2, p less than 0. 025. During insulin-induced hypoglycemia the growth <b>hormone</b> <b>levels</b> rose to values which in osteoarthrotic women {{were significantly higher than}} in osteoporotics and in control subjects. status: publishe...|$|R
40|$|The aim of {{this study}} was to {{determine}} the alterations in thyroid function during carbamazepine or valproate monotherapy in a prospective study. Forty patients treated with valproate, 33 patients treated with carbamazepine, and 36 control patients, all aged between 2 and 18 years, were enrolled in our study. Serum <b>levels</b> of thyroid <b>hormones</b> were measured before the beginning of the antiepileptic therapy and at 6 and 12 months of treatment. Carbamazepine-treated patients showed mean serum thyroid <b>hormone</b> <b>levels</b> significantly lower than baseline evaluation and the control group. Thyroid-stimulating <b>hormone</b> <b>levels</b> at 6 and 12 months were not significantly different in carbamazepine treated patients. Serum <b>hormone</b> <b>levels</b> did not change during valproate treatment. Thyroid-stimulating <b>hormone</b> <b>levels</b> were significantly higher at the 12 th month of valproate treatment. Our data suggest that although carbamazepine causes significant alterations in thyroid <b>hormone</b> <b>levels,</b> these changes do not lead to clinical symptoms at the follow-up period of 12 months...|$|R
2500|$|BHRT is {{frequently}} associated with testing of saliva {{to establish a}} baseline <b>hormone</b> <b>level</b> and compounding of the substances by pharmacists (according to a doctor's advice) to produce preparations (and blood levels) of hormones that are individualized to the patients. There is no research demonstrating any benefit to either of these practices. Though promoters of BHRT claim that saliva testing {{can be used to}} [...] "customize" [...] the level of hormones for individuals, and tests are used to determine which hormones are supposed to be deficient and require supplementation, there is no scientific basis to support the use of saliva testing. Estrogens are secreted in pulses within and over days, resulting in varying saliva levels. [...] Certain compounding formulations also attempt to use a single profile for all women, with no evidence that a specific profile is beneficial in all cases and no recognition that women differ in their sensitivity to hormones and metabolic rate. [...] Testing-based customizing also does not account for much of the effects, and synthesis of hormones occurs within tissues rather than in the blood; therefore, blood or saliva levels of hormones may not necessarily reflect actual biological activity. [...] Other concerns include lack of evidence that samples are stable during storage and transportation, poor replication of results and considerable variation among assays. [...] There are also no studies that link symptoms with blood or saliva levels of hormones. [...] The FDA recommends, instead, adjusting hormone therapy to the symptoms of the patient, {{and there is no reason}} to adjust the dosing or monitor patients receiving BHRT. [...] Skeptics of BHRT have also pointed out that there is no certainty regarding hormone levels in the body. [...] The North American Menopause Society has supported warnings about the potential harm BHRT could cause, as it unnecessarily compounds drugs that are already FDA-approved in ways that lack an evidence base of safety or harm; this warning is supported by the Society of Obstetricians and Gynaecologists of Canada.|$|E
5000|$|TSH [...] - [...] A thyroid-stimulating <b>hormone</b> <b>level</b> {{should be}} {{obtained}} first. If it is suppressed, then the nodule is likely a hyperfunctioning (or [...] "hot") nodule. These are rarely malignant.|$|E
5000|$|Relatively {{high amount}} of rutin {{increases}} thyroid iodide uptake in rats and decreases serum T3 and T4 level. The decreased <b>hormone</b> <b>level</b> {{can be explained}} by its inhibitory effect produced on Thyroid peroxidase enzyme (TPO).|$|E
50|$|Even when {{surgery is}} {{successful}} and <b>hormone</b> <b>levels</b> return to normal, patients {{must be carefully}} monitored for years for possible recurrence. More commonly, <b>hormone</b> <b>levels</b> may improve, but not return completely to normal. These patients may then require additional treatment, usually with medications.|$|R
50|$|Tests include {{observable}} lack of testes, low {{testosterone levels}} (typical female levels), elevated {{follicle stimulating hormone}} and luteinizing <b>hormone</b> <b>levels,</b> XY karyotype, ultrasound or magnetic resonance imaging showing absent gonadal tissue, low bone density, low anti-Müllerian <b>hormone</b> <b>levels,</b> and surgical exploration for evidence of male gonadal tissue.|$|R
5000|$|Suppressing <b>hormone</b> <b>levels</b> in {{transsexual}} people, especially trans women.|$|R
50|$|The {{evaluation}} of atrial fibrillation involves {{a determination of}} {{the cause of the}} arrhythmia, and classification of the arrhythmia. Diagnostic investigation of AF typically includes a complete history and physical examination, ECG, transthoracic echocardiogram, complete blood count, and serum thyroid stimulating <b>hormone</b> <b>level.</b>|$|E
50|$|For simplicity, let’s {{say that}} the doctor first {{receives}} the blood test (in formulas abbreviated as “BT”) result for the parathyroid hormone analysis, and that it showed a parathyroid <b>hormone</b> <b>level</b> that is elevated relatively to what would be expected by the calcium level.|$|E
50|$|Serum calcium {{levels are}} elevated, and the {{parathyroid}} <b>hormone</b> <b>level</b> is abnormally high {{compared with an}} expected low level {{in response to the}} high calcium. A relatively elevated parathyroid hormone has been estimated to have a sensitivity of 60%-80% and a specificity of approximately 90% for primary hyperparathyroidism.|$|E
40|$|We {{measured}} serum anti-Müllerian <b>hormone</b> <b>levels</b> {{before and}} after surgery in women undergoing unilateral and monolocular cystectomy for benign ovarian diseases. Comparing to control benign cysts, we found a significant decline in serum anti-Müllerian <b>hormone</b> <b>levels</b> with consequent depletion of follicles in tissue specimens after surgery for women with ovarian endometrioma...|$|R
5000|$|... #Subtitle <b>level</b> 4: Sex <b>hormone</b> <b>levels</b> and the {{menstrual cycle}} ...|$|R
40|$|Abstract Background Numerous {{studies have}} {{reported}} that age-induced increased parathyroid <b>hormone</b> plasma <b>levels</b> are associated with cognitive decline and dementia. Little {{is known about the}} correlation that may exist between neurological processing speed, cognition and bone density in cases of hyperparathyroidism. Thus, we decided to determine if parathyroid <b>hormone</b> <b>levels</b> correlate to processing speed and/or bone density. Methods The recruited subjects that met the inclusion criteria (n = 92, age-matched, age 18 - 90 years, mean = 58. 85, SD = 15. 47) were evaluated for plasma parathyroid <b>hormone</b> <b>levels</b> and these levels were statistically correlated with event-related P 300 potentials. Groups were compared for age, bone density and P 300 latency. One-tailed tests were used to ascertain the statistical significance of the correlations. The study groups were categorized and analyzed for differences of parathyroid hormone levels: parathyroid <b>hormone</b> <b>levels</b> 30 (n = 62, mean = 62. 4 ± 28. 3 SD, p ≤ 02). Results Patients with parathyroid <b>hormone</b> <b>levels</b> 30, which demonstrated greater P 300 latency (P 300 = 345. 7 ± 3. 6 SE, p =. 02). Participants with parathyroid hormone values 30 (n = 48, M = - 1. 85 ±. 19 SE, p =. 04). Conclusion Our findings of a statistically lower bone density and prolonged P 300 in patients with high parathyroid <b>hormone</b> <b>levels</b> may suggest that increased parathyroid <b>hormone</b> <b>levels</b> coupled with prolonged P 300 latency may become putative biological markers of both dementia and osteoporosis and warrant intensive investigation. </p...|$|R
50|$|The Abbott AxSYM is an immunochemical {{automated}} analyzer made by Abbott Laboratories. It is {{used for}} serology tests and therapeutic drug monitoring, and uses antibodies to alter the deflection of polarized light. It {{can also be used}} to monitor <b>hormone</b> <b>level</b> and some cardiac markers such as troponin.|$|E
50|$|A more {{powerful}} variant of comparing {{the balance between}} calcium and parathyroid hormone is to perform a 3-hour calcium infusion. After infusion, a parathyroid <b>hormone</b> <b>level</b> above a cutoff of 14 ng/l has a sensitivity of 100% and a specificity of 93% in detecting primary hyperparathyroidism, with a confidence interval of 80% to 100%.|$|E
5000|$|In {{extremely}} rare cases, a malignant tumor may develop within the parathyroid gland. They {{can be detected}} intraoperatively, imaging, or through blood testing. A thick fibrous capsule is usually present around the gland, {{as opposed to the}} thin capsule present in benign adenomas. [...] Parathyroid <b>hormone</b> <b>level</b> is often greater in carcinomas than in benign disorders.|$|E
40|$|Objective. The {{present study}} was aimed to {{elucidate}} the dynamic changes of endogenous <b>hormone</b> <b>levels</b> during the fruit growth and the changing regulation of endogenous <b>hormone</b> <b>levels</b> between normal and abnormal fruits. Methods. After using exogenous GA 3 and GA 3 + 6 -BA, endogenous <b>hormone</b> <b>levels</b> such as indoleacetic acid(IAA), cytokinin(ZR), abscisic acid(ABA) and gibberellin(GA 3) in normal fruits and rigid abnormal ones were determined by enzyme-linked immunosorbent assays(ELISA), respectively. Results. The {{results indicated that the}} treatments of 20 mg/kg GA 3 and the combination of 20 mg/kg GA 3 + 10 mg/kg 6 -BA had no remarkable effects on increasing average weight of berries where the vertical diameter of grape fruits was longer than the transverse diameter. Exogenous hormone GA 3 and GA 3 + 6 -BA mixture also affected the endogenous <b>hormone</b> <b>levels.</b> The content of IAA, ABA and ZR was lower in the rigid abnormal fruits than that in the normal ones, respectively, and those levels during the rapid growth period were nearly in accordance with those during the slow growth period. Conclusion. The fruit growth was closely related to the endogenous <b>hormone</b> <b>levels...</b>|$|R
30|$|Similarly, anticonvulsants, {{including}} lamotrigine and valproic acid, {{have been}} shown to increase parathyroid <b>hormone</b> <b>levels</b> in patients with epilepsy (Kim et al. 2007). Therefore, the differences in parathyroid <b>hormone</b> <b>levels</b> found in our study are unlikely to be brought about by the higher number of patients in the non-lithium group being on valproic acid or lamotrigine.|$|R
50|$|Oral {{administration}} of sufugolix at {{a dose of}} 30 mg/kg to castrated male cynomolgus monkeys resulted in nearly complete suppression of luteinizing <b>hormone</b> <b>levels.</b> The duration of action was more than 24 hours, indicating a long half-life of the drug. The suppressive effects of sufugolix on gonadotropin and sex <b>hormone</b> <b>levels</b> are rapidly reversible with discontinuation.|$|R
50|$|Estrogen is {{considered}} to {{play a significant role}} in women’s mental health, with links suggested between the <b>hormone</b> <b>level,</b> mood and well-being. Sudden drops or fluctuations in, or long periods of sustained low levels of estrogen may be correlated with significant mood-lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized and/or restored.|$|E
50|$|Pseudohypoparathyroidism is a {{condition}} associated primarily with resistance to the parathyroid hormone. Those with the condition have a low serum calcium and high phosphate, but the parathyroid <b>hormone</b> <b>level</b> (PTH) is appropriately high (due to {{the low level of}} calcium in the blood). Its pathogenesis has been linked to dysfunctional G Proteins (in particular, Gs alpha subunit). The condition is extremely rare, with an estimated overall prevalence of 7.2/1,000,000 or approximately 1/140000.|$|E
50|$|The <b>hormone</b> <b>level</b> {{differences}} {{between males and}} destrous females can be shown by the differences in Kiss 1 mRNA expression {{between male and female}} rats during their neonatal period (time period between existing in the maternal uterus and existing completely independently). A single-labeled ISH was used to compare levels of Kiss 1 mRNA in AVPV and ARC originating from adult females that were treated with thymopoietin pentapeptide on the day they were born.|$|E
40|$|OBJECTIVES. Establishing {{pediatric}} reference intervals {{has always}} been challenging, with most ranges used in pediatric laboratories developed over many years. The clinical interpretation of gonadotropins {{is important in the}} context of ambiguous genitalia. The aim {{of this study was to}} develop reference intervals for luteinizing hormone and follicle-stimulating hormone in infants born between 24 and 29 weeks&# 039; gestation. METHODS. Samples were collected at 0 to 43 days after birth from 82 premature infants born < 30 weeks&# 039; gestation for analysis of luteinizing hormone and follicle-stimulating hormone by automated immunochemiluminometric immunoassays. RESULTS. The 43 male infants demonstrated a range of luteinizing <b>hormone</b> <b>levels</b> from 0. 1 to 13. 4 IU/L and of follicle-stimulating <b>hormone</b> <b>levels</b> from 0. 3 to 4. 6 IU/L. The 39 female infants demonstrated a range of luteinizing <b>hormone</b> <b>levels</b> from 0. 2 to 54. 4 IU/L and of follicle-stimulating <b>hormone</b> <b>levels</b> from 1. 2 to 167. 0 IU/L. The ratio of luteinizing hormone/follicle-stimulating <b>hormone</b> <b>levels</b> differed with males, ranging from 0. 3 to 9. 4, and females, at < 0. 5. CONCLUSION. These data provide guidance for the interpretation of luteinizing hormone and follicle-stimulating <b>hormone</b> <b>levels</b> for the first 6 weeks of life in extremely premature infants born between 24 and 29 weeks&# 039; gestation. The availability of age-appropriate reference intervals is essential for correct and timely interpretation of biochemical results to the clinician. Copyright © 2008 by the American Academy of Pediatrics...|$|R
5000|$|... #Caption: The {{effect of}} {{relative}} rank on stress <b>hormone</b> <b>levels</b> in savanna baboons ...|$|R
30|$|Cystic {{change is}} {{significantly}} related to the size, weight and measured parathyroid <b>hormone</b> <b>levels.</b>|$|R
50|$|Scanty menses or periods {{can occur}} {{normally}} at {{the extremes of}} the reproductive life that is, just after puberty and just before menopause. This is because ovulation is irregular at this time, and the endometrial lining fails to develop normally.But normal problems at other times can also cause scanty blood flow. Anovulation due to a low thyroid <b>hormone</b> <b>level,</b> high prolactin level, high insulin level, high androgen level and problems with other hormone can also cause scanty periods.|$|E
5000|$|Takioullah {{was born}} in Guelmim, Morocco, in 1982. At the age of 18, he had been asked by his school doctor to get a blood test, for his [...] "unusual" [...] size. Diagnosed with acromegaly, Takioullah, {{in a single year}} had a metre high growth spurt. After obtaining his {{university}} degree in geography, a French doctor brought Takioullah to Paris in 2006, for treatment.His treatment was successful as his tumour was removed and the growth <b>hormone</b> <b>level</b> in his blood was brought down to normal.His heart was also reported in a good condition.|$|E
5000|$|By {{knowing which}} of the four {{parathyroid}} glands is hyperfunctioning, a surgeon is able to remove only the one parathyroid gland that is producing excessive amounts of parathyroid hormone and no longer under the biochemical control of the body, and leave the other 3 normal parathyroid glands in place. This operation is now termed a [...] "minimally invasive parathyroidectomy", sometimes using a radionuclear detection probe, and correlated with intra-operative parathyroid <b>hormone</b> <b>level</b> measurements. The remaining 3 glands are able to properly regulate serum calcium levels appropriately after {{the resolution of the}} hypercalcemia, as the calcium receptors lead to stimulation of parathyroid hormone secretion.|$|E
40|$|Background: Much {{research}} has widely been conducted into thyroid <b>hormones</b> <b>levels</b> following radiotherapy for breast cancer. Consequently, in this study, we evaluated {{to relate the}} rate of thyroid <b>hormones</b> <b>levels</b> with the dose distribution among breast cancer patients. Material and Methods: Thirty patients were treated with 4 -field breast cancer radiotherapy. The dose volume histograms, the volume percentage of the thyroid absorbing respectively 20, 30, 40 and 50 Gy were then estimated (V 20, V 30, V 40 and V 50) together with the individual average thyroid dose over the whole gland derived from their computed tomography-based treatment plans. Then, in serum samples triiodothyronine [T 3], thyroxine [T 4], thyroid-stimulating hormone [TSH] of the patients were measured before and after radiotherapy. Results: There {{were no significant differences}} in thyroid <b>hormones</b> <b>levels</b> before and after radiotherapy for patients with breast cancer (P value >. 05). Conclusion: On the balance, we understood that thyroid stimulating <b>hormones</b> <b>levels</b> did not change before and after cancer breast radiotherap...|$|R
40|$|Previous {{research}} has found that <b>hormone</b> <b>levels</b> change throughout the phases of the menstrual cycle and can affect menstrual distress, however, with inconsistent results. Additionally, {{research has}} indicated that stress plays a role in menstrual distress symptoms. There has not been a comprehensive study to date which examines the relationship of reproductive <b>hormone</b> <b>levels</b> (e. g., progesterone, estradiol, LH and PRL) throughout all four phases of the menstrual cycle, while also studying menstrual distress symptoms and indices of stress. Participants include a community sample of women (N = 37) recruited at a university medical center in Mississippi who completed laboratory hormone assays, as well as the Menstrual Distress Questionnaire (Moos, 1968), the Weekly Stress Inventory (Brantley, Jones, Boudreaux, 2 ̆ 6 Catz, 1997), and a global stress measure, throughout four phases of one menstrual cycle. Pearson correlations were conducted to test the potential relationships of <b>hormone</b> <b>levels</b> and indices of stress. The relationships between <b>hormone</b> <b>levels</b> and menstrual distress, as well as the relationships between menstrual distress and stress also were examined. Potential interactions were examined using multiple regressions. The role of menstrual distress in mediating the relationship between <b>hormone</b> <b>levels</b> and indices of stress also were considered and assessed using a series of multiple regression equations...|$|R
40|$|We {{measured}} parathyroid <b>hormone</b> <b>levels</b> in {{pregnant and}} nonpregnant women and at 1, 2 and 5 days {{of life in}} healthy term neonates and in hypocalcemic preterm infants using a new immunoradiometric assay which measures only biologically active intact parathyroid hormone and by a mid-molecule parathyroid hormone radioimmunoassay. During pregnancy intact and mid-molecule parathyroid <b>hormone</b> <b>levels</b> did not show any modification and were not different from parathyroid <b>hormone</b> <b>levels</b> of nonpregnant age-matched controls. Serum calcium and phosphorus levels did not vary during each trimester of pregnancy. In cord serum intact and mid-molecule parathyroid hormone values were low in both term and preterm infants. In term neonates intact and mid-molecule parathyroid <b>hormone</b> <b>levels</b> peaked on day 1; in preterm infants intact parathyroid <b>hormone</b> <b>levels</b> peaked on day 1 while mid-molecule parathyroid hormone values peaked on day 2. Intact parathyroid <b>hormone</b> <b>levels</b> showed a more marked increase in preterm (19 -fold) than in term neonates (7. 5 -fold) on day 1. Our data do not confirm the previously reported "physiologic" hyperparathyroidism in pregnancy. Moreover we found a normal parathyroid gland responsiveness to decreasing serum calcium levels {{in the first days}} of life in term and preterm infants. Our results suggest that measurement of intact parathyroid hormone 1 - 84 by immunora-diometric assay in the first days of life is a more sensitive index of parathyroid gland secretory function than the measurement of middle or carboxyl-terminal parathyroid hormone fragments allowing the detection of the dynamic changes of parathyroid hormone which occur in hypocalcemic preterm infants...|$|R
